In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), Finepoint Capital LP reported 17 stock positions worth $351.8 million . Its top holding was Liberty Broadband-C (LBRDK) at 31.1% of the portfolio, followed by Revolution Medicines (RVMD, 8.0% ) and Ascendis Pharma A/S (ASND, 7.3% ). Compared with Q1 2024, it added to 14 and reduced 1. The biggest buy was Liberty Broadband-C (LBRDK, shares +6% ) and the biggest sale Sarepta Therapeutics (SRPT, shares −16% ).
Location BOSTON, MA
CIK 0001608126
Portfolio Value $351.8M (Q2 2024) Holdings 17 stocks · $351.8M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q1 2024 LBRDK Liberty Broadband-C 1,994,510 $109.3M Add +5.7% RVMD Revolution Medicines Inc. 729,464 $28.3M Add +7.7% ASND Ascendis Pharma A/S 189,272 $25.8M Add +7.7% SWTX Springworks Therapeutics Inc. 638,352 $24.0M Add +7.7% ARGX Argenx SE - ADR 54,028 $23.2M Add +8.1% SRPT Sarepta Therapeutics Inc. 132,835 $21.0M Reduce -16.2% MLTX Moonlake Immunotherapeutics 388,835 $17.1M Add +7.7% ARVN Arvinas Inc. 574,378 $15.3M Add +6.5% ACAD Acadia Pharmaceuticals Inc. 905,384 $14.7M Add +7.7% TVTX Travere Therapeutics Inc. 1,776,728 $14.6M Add +7.7% CYTK Cytokinetics Inc. 256,449 $13.9M Add +7.7% LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV 542,762 $13.4M Add +7.7% RLAY Relay Therapeutics Inc. 1,605,346 $10.5M Add +7.7% PRTA Prothena Corp. PLC 433,471 $8.9M Add +7.7% EYPT Eyepoint Inc. 707,404 $6.2M Add +7.7% SLDB Solid Biosciences Inc. 961,251 $5.5M No change CALIDI BIOTHERAPEUTICS INC 125,000 $25K No change
Other holdings (8): bonds, preferreds, convertibles and warrants · $463K (not counted above) Security Class Shares / Principal Value Change CVIIW Churchill Capital Vii -CW28 *W EXP 02/29/202 548,000 $192K No change MNYWW Moneyhero Ltd.-28 *W EXP 09/13/202 895,000 $72K No change CNDAW Concord Acquisition A -CW28 *W EXP 99/99/999 408,333 $45K No change IVCPW Swiftmerge Acquisition -CW23 *W EXP 12/13/202 490,000 $39K No change LAKESHORE BIOPHARMA CO LTD *W EXP 03/15/202 489,999 $33K No change CLDWW Calidi Biotherapeutics -CW23 *W EXP 03/14/202 655,200 $28K No change CDAWF Compass Digital Acq -CW28 *W EXP 99/99/999 459,906 $28K No change GATEW Marblegate Acquisition -CW22 *W EXP 08/31/202 735,000 $27K No change
Total filed on the 13F, all lines: $352.3M.
Portfolio Sells Q1 2024 → Q2 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2024 % Of Portfolio Change To Portfolio ▲ SRPT Sarepta Therapeutics Inc. Reduce -16.2% 5.97% +0.51
Portfolio Buys Q1 2024 → Q2 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2024 % Of Portfolio Change To Portfolio ▼ LBRDK Liberty Broadband-C Add +5.7% 31.08% +2.37 RVMD Revolution Medicines Inc. Add +7.7% 8.05% +2.24 ARGX Argenx SE - ADR Add +8.1% 6.60% +1.37 TVTX Travere Therapeutics Inc. Add +7.7% 4.15% +0.77 ASND Ascendis Pharma A/S Add +7.7% 7.34% +0.27 ACAD Acadia Pharmaceuticals Inc. Add +7.7% 4.18% +0.05 MLTX Moonlake Immunotherapeutics Add +7.7% 4.86% +0.04 PRTA Prothena Corp. PLC Add +7.7% 2.54% −0.11 RLAY Relay Therapeutics Inc. Add +7.7% 2.98% −0.31 CYTK Cytokinetics Inc. Add +7.7% 3.95% −0.49 LKFT Lakefront Biotherapeutic-ADR Add +7.7% 3.82% −0.49 SWTX Springworks Therapeutics Inc. Add +7.7% 6.83% −0.92 ARVN Arvinas Inc. Add +6.5% 4.35% −1.57 EYPT Eyepoint Inc. Add +7.7% 1.75% −1.86
Notes & Other Activity Q1 2024 → Q2 2024 Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 4 $460.8M QXO, RXO, ANNA, CLDI Q1 2026 4 $416.6M QXO, RXO, ANNA, CLDI Q4 2025 5 $532.7M QXO, RXO, SLDB, ANNA, CLDI Q3 2025 5 $542.8M QXO, RXO, SLDB, ANNA, CLDI Q2 2025 5 $504.1M QXO, LLYVK, SLDB, ANNA, CLDI Q1 2025 19 $592.5M QXO, LBRDK, SWTX, LLYVK, ASND Q4 2024 20 $866.7M QXO, LBRDK, LLYVK, ARGX, RVMD Q3 2024 18 $822.2M QXO, LBRDK, RVMD, ARGX, ASND Q2 2024 17 $351.8M LBRDK, RVMD, ASND, SWTX, ARGX Q1 2024 17 $376.0M LBRDK, SWTX, ASND, ARVN, RVMD